<?xml version='1.0' encoding='utf-8' standalone='yes'?>
<collection>
  <source></source>
  <date>2021-07-08</date>
  <key></key>
  <document>
    <id>17167170</id>
    <passage>
      <offset>0</offset>
      <text>Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.	Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes. The PPARdelta subtype has the highest expression in the brain and is postulated to play a major role in neuronal cell function; however, the precise physiological roles of this receptor remain to be elucidated. Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo. In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition. In the transient (90 min) middle cerebral artery occlusion model of ischemic brain injury in rats, i.c.v. infusion of L-165041 or GW501516 significantly attenuated the ischemic brain damage measured 24 h after reperfusion. Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain. These results demonstrate that subtype-selective PPARdelta agonists possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD). These findings suggest that PPARdelta agonists could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.</text>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptors</infon>
          <location offset="122" length="43"/>
          <text>Peroxisome proliferator-activated receptors</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppars</infon>
          <location offset="167" length="5"/>
          <text>PPARs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>347</offset>
        <text>The PPARdelta subtype has the highest expression in the brain and is postulated to play a major role in neuronal cell function; however, the precise physiological roles of this receptor remain to be elucidated.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppardelta</infon>
          <location offset="351" length="9"/>
          <text>PPARdelta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>558</offset>
        <text>Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-165041</infon>
          <location offset="616" length="8"/>
          <text>L-165041</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid</infon>
          <location offset="626" length="71"/>
          <text>4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw501516</infon>
          <location offset="703" length="8"/>
          <text>GW501516</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid</infon>
          <location offset="713" length="101"/>
          <text>2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</infon>
          <location offset="914" length="44"/>
          <text>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="960" length="4"/>
          <text>MPTP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>989</offset>
        <text>In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-165041</infon>
          <location offset="1028" length="8"/>
          <text>L-165041</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw501516</infon>
          <location offset="1040" length="8"/>
          <text>GW501516</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thapsigargin</infon>
          <location offset="1125" length="12"/>
          <text>thapsigargin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-methyl-4-phenylpyridinium</infon>
          <location offset="1139" length="27"/>
          <text>1-methyl-4-phenylpyridinium</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">staurosporine</infon>
          <location offset="1171" length="13"/>
          <text>staurosporine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1250" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T14" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>In the transient (90 min) middle cerebral artery occlusion model of ischemic brain injury in rats, i.c.v. infusion of L-165041 or GW501516 significantly attenuated the ischemic brain damage measured 24 h after reperfusion.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-165041</infon>
          <location offset="1390" length="8"/>
          <text>L-165041</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw501516</infon>
          <location offset="1402" length="8"/>
          <text>GW501516</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1495</offset>
        <text>Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="1558" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1593" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1650</offset>
        <text>These results demonstrate that subtype-selective PPARdelta agonists possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD).</text>
      </sentence>
      <sentence>
        <offset>1904</offset>
        <text>These findings suggest that PPARdelta agonists could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppardelta</infon>
          <location offset="2003" length="9"/>
          <text>PPARdelta</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17276892</id>
    <passage>
      <offset>0</offset>
      <text>Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.	Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities. We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs). Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha). It also blocked the TNF-alpha-induced phosphorylation of p38 and extracellular signal-regulated kinase (ERK), which are involved in regulating ICAM-1 production by TNF-alpha. Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha. The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production. Thus, paeonol may be beneficial in the treatment of cardiovascular disorders such as atherosclerosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="0" length="7"/>
          <text>Paeonol</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">intercellular adhesion molecule-1</infon>
          <location offset="19" length="33"/>
          <text>intercellular adhesion molecule-1</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-alpha</infon>
          <location offset="67" length="27"/>
          <text>tumor necrosis factor-alpha</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p38</infon>
          <location offset="157" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk</infon>
          <location offset="162" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nuclear factor-kappab</infon>
          <location offset="170" length="21"/>
          <text>nuclear factor-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T1" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>212</offset>
        <text>Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="212" length="7"/>
          <text>Paeonol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2'-hydroxy-4'-methoxyacetophenone</infon>
          <location offset="221" length="33"/>
          <text>2'-hydroxy-4'-methoxyacetophenone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>425</offset>
        <text>We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">intercellular adhesion molecule-1</infon>
          <location offset="454" length="33"/>
          <text>intercellular adhesion molecule-1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="489" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="583" length="7"/>
          <text>paeonol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-alpha</infon>
          <location offset="594" length="27"/>
          <text>tumor necrosis factor-alpha</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="623" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>693</offset>
        <text>Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="693" length="7"/>
          <text>Paeonol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="755" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nuclear factor-kappab</infon>
          <location offset="776" length="21"/>
          <text>nuclear factor-kappaB</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="799" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="810" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inhibitory factor kappabalpha</infon>
          <location offset="872" length="29"/>
          <text>inhibitory factor kappaBalpha</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappabalpha</infon>
          <location offset="903" length="12"/>
          <text>IkappaBalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>918</offset>
        <text>It also blocked the TNF-alpha-induced phosphorylation of p38 and extracellular signal-regulated kinase (ERK), which are involved in regulating ICAM-1 production by TNF-alpha.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="938" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p38</infon>
          <location offset="975" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk</infon>
          <location offset="1022" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="1061" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="1082" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1093</offset>
        <text>Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="1093" length="7"/>
          <text>Paeonol</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="1158" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="1303" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1314</offset>
        <text>The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="1339" length="7"/>
          <text>paeonol</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="1350" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p38</infon>
          <location offset="1400" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk</infon>
          <location offset="1405" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1413" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="1465" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="1483" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T36" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T36" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T36" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T36" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1502</offset>
        <text>Thus, paeonol may be beneficial in the treatment of cardiovascular disorders such as atherosclerosis.</text>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paeonol</infon>
          <location offset="1508" length="7"/>
          <text>paeonol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17293381</id>
    <passage>
      <offset>0</offset>
      <text>Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.	Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation. We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted CYP3A inactivation in hepatocytes. In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites. In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml. MD did not inactivate CYP3A. Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent. MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively. In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations. In addition, the metabolites appeared to be accumulated inside the cells. In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem. These findings suggest that prediction of CYP3A loss based solely on microsomal inactivation parameters of parent drug may be inadequate.</text>
      <sentence>
        <offset>0</offset>
        <text>Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="41" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="82" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T1" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>89</offset>
        <text>Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation.</text>
      </sentence>
      <sentence>
        <offset>206</offset>
        <text>We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted CYP3A inactivation in hepatocytes.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="280" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="305" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T4" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>340</offset>
        <text>In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="431" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="440" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="471" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">md</infon>
          <location offset="496" length="2"/>
          <text>MD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>513</offset>
        <text>In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="540" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="591" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="683" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T14" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>745</offset>
        <text>MD did not inactivate CYP3A.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">md</infon>
          <location offset="745" length="2"/>
          <text>MD</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="767" length="5"/>
          <text>CYP3A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>774</offset>
        <text>Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="790" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="799" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="888" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="989" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="1037" length="2"/>
          <text>MA</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T23" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1092</offset>
        <text>MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="1092" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">md</infon>
          <location offset="1099" length="2"/>
          <text>MD</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1132" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T27" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T26" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1202</offset>
        <text>In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="1246" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1280" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="1328" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">md</infon>
          <location offset="1335" length="2"/>
          <text>MD</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="1348" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="1387" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T34" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T32" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1413</offset>
        <text>In addition, the metabolites appeared to be accumulated inside the cells.</text>
      </sentence>
      <sentence>
        <offset>1487</offset>
        <text>In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem.</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1514" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ma</infon>
          <location offset="1536" length="2"/>
          <text>MA</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1601" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diltiazem</infon>
          <location offset="1670" length="9"/>
          <text>diltiazem</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T37" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1681</offset>
        <text>These findings suggest that prediction of CYP3A loss based solely on microsomal inactivation parameters of parent drug may be inadequate.</text>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1723" length="5"/>
          <text>CYP3A</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17304149</id>
    <passage>
      <offset>0</offset>
      <text>Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.	A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein. However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of paroxetine. The aim of this study was to examine the effects of itraconazole, a P-glycoprotein inhibitor, on the pharmacokinetics of paroxetine. Two 6 day courses of either 200 mg itraconazole daily or placebo with at least a 4 week washout period were conducted. Thirteen volunteers took a single oral 20 mg dose of paroxetine on day 6 of both courses. Plasma concentrations of paroxetine were monitored up to 48 hours after the dosing. Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P &lt; 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P &lt; 0.01). Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P &lt; 0.05), the alteration was small (1.1 fold). The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="10" length="12"/>
          <text>itraconazole</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="46" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="127" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="156" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T3" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>172</offset>
        <text>However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of paroxetine.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="244" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="286" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>298</offset>
        <text>The aim of this study was to examine the effects of itraconazole, a P-glycoprotein inhibitor, on the pharmacokinetics of paroxetine.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="350" length="12"/>
          <text>itraconazole</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="419" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>431</offset>
        <text>Two 6 day courses of either 200 mg itraconazole daily or placebo with at least a 4 week washout period were conducted.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="466" length="12"/>
          <text>itraconazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>550</offset>
        <text>Thirteen volunteers took a single oral 20 mg dose of paroxetine on day 6 of both courses.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="603" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>640</offset>
        <text>Plasma concentrations of paroxetine were monitored up to 48 hours after the dosing.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="665" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>724</offset>
        <text>Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P &lt; 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P &lt; 0.01).</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="747" length="12"/>
          <text>itraconazole</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="834" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="999" length="10"/>
          <text>paroxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1072</offset>
        <text>Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P &lt; 0.05), the alteration was small (1.1 fold).</text>
      </sentence>
      <sentence>
        <offset>1215</offset>
        <text>The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="1274" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="1302" length="12"/>
          <text>itraconazole</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="1353" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="1395" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17345086</id>
    <passage>
      <offset>0</offset>
      <text>Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.	PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents. We previously reported that some flavonoids have BCRP-inhibitory activity. Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance. METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays. The IC(50) values were determined from the growth inhibition curves. The RI(50) values were then determined as the concentration of inhibitor that causes a twofold reduction of the IC(50) in each transfectant. The reversal of BCRP activity was tested by measuring the fluorescence of intracellular topotecan. RESULTS: The BCRP-inhibitory activity of 32 compounds was screened, and 20 were found to be active. Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone. We next examined the effects of a panel of 11 compounds on P-gp- and MRP1-mediated drug resistance. Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp. None of the flavonoids that we tested inhibited MRP1. CONCLUSION: Our present results thus indicate that many flavonoids selectively inhibit BCRP only. Moreover, we examined the structure-BCRP inhibitory activity relationship from our current study.</text>
      <sentence>
        <offset>0</offset>
        <text>Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="0" length="10"/>
          <text>Flavonoids</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">breast cancer resistance protein</infon>
          <location offset="19" length="32"/>
          <text>breast cancer resistance protein</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T1" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>139</offset>
        <text>PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atp-binding cassette</infon>
          <location offset="148" length="20"/>
          <text>ATP-binding cassette</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="197" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="213" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">breast cancer resistance protein</infon>
          <location offset="220" length="32"/>
          <text>breast cancer resistance protein</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="254" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">multidrug resistance-related protein 1</infon>
          <location offset="265" length="38"/>
          <text>multidrug resistance-related protein 1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="305" length="4"/>
          <text>MRP1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>360</offset>
        <text>We previously reported that some flavonoids have BCRP-inhibitory activity.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="393" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="409" length="4"/>
          <text>BCRP</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T10" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>435</offset>
        <text>Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="494" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="510" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="517" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="528" length="4"/>
          <text>MRP1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>559</offset>
        <text>METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="588" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="604" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="611" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="621" length="4"/>
          <text>MRP1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="672" length="4"/>
          <text>BCRP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>827</offset>
        <text>The IC(50) values were determined from the growth inhibition curves.</text>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>The RI(50) values were then determined as the concentration of inhibitor that causes a twofold reduction of the IC(50) in each transfectant.</text>
      </sentence>
      <sentence>
        <offset>1037</offset>
        <text>The reversal of BCRP activity was tested by measuring the fluorescence of intracellular topotecan.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1053" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">topotecan</infon>
          <location offset="1125" length="9"/>
          <text>topotecan</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>RESULTS: The BCRP-inhibitory activity of 32 compounds was screened, and 20 were found to be active.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1149" length="4"/>
          <text>BCRP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1236</offset>
        <text>Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3',4',7-trimethoxyflavone</infon>
          <location offset="1266" length="25"/>
          <text>3',4',7-trimethoxyflavone</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1318" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sn-38</infon>
          <location offset="1371" length="5"/>
          <text>SN-38</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mitoxantrone</infon>
          <location offset="1395" length="12"/>
          <text>mitoxantrone</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T26" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1409</offset>
        <text>We next examined the effects of a panel of 11 compounds on P-gp- and MRP1-mediated drug resistance.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1468" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="1478" length="4"/>
          <text>MRP1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1509</offset>
        <text>Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.</text>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3',4',7-trimethoxyflavone</infon>
          <location offset="1530" length="25"/>
          <text>3',4',7-trimethoxyflavone</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acacetin</infon>
          <location offset="1560" length="8"/>
          <text>acacetin</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1591" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1667" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1673</offset>
        <text>None of the flavonoids that we tested inhibited MRP1.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="1685" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="1721" length="4"/>
          <text>MRP1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1727</offset>
        <text>CONCLUSION: Our present results thus indicate that many flavonoids selectively inhibit BCRP only.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="1783" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1814" length="4"/>
          <text>BCRP</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1825</offset>
        <text>Moreover, we examined the structure-BCRP inhibitory activity relationship from our current study.</text>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1861" length="4"/>
          <text>BCRP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17395790</id>
    <passage>
      <offset>0</offset>
      <text>Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.	Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective oxytocin receptor antagonist GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione. GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with &gt;1,400-fold selectivity over human V1a, V1b, and V2 receptors. GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18. Intravenous administration of GSK221149A produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml). Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing. Spontaneous uterine contractions in late-term pregnant rats (19-21 days gestation) were significantly reduced by intravenous administration of 0.3 mg/kg of GSK221149A. These results provide further evidence that selective oxytocin receptor antagonism may offer an effective treatment for preterm labor.</text>
      <sentence>
        <offset>0</offset>
        <text>Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.</text>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective oxytocin receptor antagonist GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="251" length="10"/>
          <text>GSK221149A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>394</offset>
        <text>GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with &gt;1,400-fold selectivity over human V1a, V1b, and V2 receptors.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="394" length="10"/>
          <text>GSK221149A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>560</offset>
        <text>GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="560" length="10"/>
          <text>GSK221149A</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="635" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="711" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>803</offset>
        <text>Intravenous administration of GSK221149A produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="833" length="10"/>
          <text>GSK221149A</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="882" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1031</offset>
        <text>Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="1054" length="10"/>
          <text>GSK221149A</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="1103" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1183</offset>
        <text>Spontaneous uterine contractions in late-term pregnant rats (19-21 days gestation) were significantly reduced by intravenous administration of 0.3 mg/kg of GSK221149A.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsk221149a</infon>
          <location offset="1339" length="10"/>
          <text>GSK221149A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1351</offset>
        <text>These results provide further evidence that selective oxytocin receptor antagonism may offer an effective treatment for preterm labor.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin receptor</infon>
          <location offset="1405" length="17"/>
          <text>oxytocin receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17402796</id>
    <passage>
      <offset>0</offset>
      <text>Adalimumab: in Crohn's disease.	Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that included a total of &gt;1400 patients. In the CLASSIC-I trial, adalimumab was significantly more effective than placebo for induction of remission in patients who had not previously received anti-TNF therapy. Adalimumab was also more effective than placebo for induction of remission in the GAIN study in patients who had either lost responsiveness or developed intolerance to infliximab. The CHARM trial showed that, among patients who responded to open-label adalimumab induction, maintenance therapy with adalimumab 40 mg weekly or every other week for up to 1 year was associated with significantly greater remission rates than placebo at weeks 26 and 56. In addition, significantly more adalimumab than placebo recipients achieved corticosteroid-free remission and had complete fistula closure. In CLASSIC-II, an extension of the CLASSIC-I trial, patients who were in remission after a short course of adalimumab and were randomized to receive up to 1 year's treatment with adalimumab 40 mg weekly or every other week were significantly more likely to remain in remission than those randomized to receive placebo. In general, the tolerability profile of adalimumab in patients with Crohn's disease was similar to that in patients with rheumatoid arthritis or other approved indications.</text>
      <sentence>
        <offset>0</offset>
        <text>Adalimumab: in Crohn's disease.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="0" length="10"/>
          <text>Adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>32</offset>
        <text>Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="32" length="10"/>
          <text>Adalimumab</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor</infon>
          <location offset="140" length="21"/>
          <text>tumor necrosis factor</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="163" length="3"/>
          <text>TNF</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T2" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>169</offset>
        <text>The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that included a total of &gt;1400 patients.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="205" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>421</offset>
        <text>In the CLASSIC-I trial, adalimumab was significantly more effective than placebo for induction of remission in patients who had not previously received anti-TNF therapy.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="445" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>591</offset>
        <text>Adalimumab was also more effective than placebo for induction of remission in the GAIN study in patients who had either lost responsiveness or developed intolerance to infliximab.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="591" length="10"/>
          <text>Adalimumab</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">infliximab</infon>
          <location offset="759" length="10"/>
          <text>infliximab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>771</offset>
        <text>The CHARM trial showed that, among patients who responded to open-label adalimumab induction, maintenance therapy with adalimumab 40 mg weekly or every other week for up to 1 year was associated with significantly greater remission rates than placebo at weeks 26 and 56.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="843" length="10"/>
          <text>adalimumab</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="890" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1042</offset>
        <text>In addition, significantly more adalimumab than placebo recipients achieved corticosteroid-free remission and had complete fistula closure.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="1074" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1182</offset>
        <text>In CLASSIC-II, an extension of the CLASSIC-I trial, patients who were in remission after a short course of adalimumab and were randomized to receive up to 1 year's treatment with adalimumab 40 mg weekly or every other week were significantly more likely to remain in remission than those randomized to receive placebo.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="1289" length="10"/>
          <text>adalimumab</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="1361" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1501</offset>
        <text>In general, the tolerability profile of adalimumab in patients with Crohn's disease was similar to that in patients with rheumatoid arthritis or other approved indications.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adalimumab</infon>
          <location offset="1541" length="10"/>
          <text>adalimumab</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17502872</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.	Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models. To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab). We analyzed the pharmacokinetics of the murine p75-Fc protein and MP6-XT22 antibody in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice. We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the murine p75-Fc protein to mice at &lt;10 mg/kg every 4-5 days, and the MP6-XT22 antibody at 10-20 mg/kg every 4-5 days.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.</text>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor</infon>
          <location offset="185" length="21"/>
          <text>tumor necrosis factor</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="208" length="3"/>
          <text>TNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>240</offset>
        <text>To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="333" length="3"/>
          <text>TNF</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">infliximab</infon>
          <location offset="460" length="10"/>
          <text>infliximab</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T8" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>We analyzed the pharmacokinetics of the murine p75-Fc protein and MP6-XT22 antibody in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice.</text>
      </sentence>
      <sentence>
        <offset>761</offset>
        <text>We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the murine p75-Fc protein to mice at &lt;10 mg/kg every 4-5 days, and the MP6-XT22 antibody at 10-20 mg/kg every 4-5 days.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17511782</id>
    <passage>
      <offset>0</offset>
      <text>Quantitative imaging of apoptosis commitment in colorectal tumor cells.	We have studied caspase-3 activation by combined DNA damage induction and EGFR kinase inhibition in order to identify potential EGFR-mediated survival signals conferring resistance to apoptosis in human colorectal tumor cells. The onset of apoptosis was microscopically imaged with a newly developed caspase-3 substrate sensor based on EGFP and tHcred1, enabling us to monitor caspase-3 activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy. Both optical approaches provide parameters quantitatively reporting the ratio between cleaved and uncleaved sensor, thereby facilitating the comparison of caspase-3 activation between different cells. Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.</text>
      <sentence>
        <offset>0</offset>
        <text>Quantitative imaging of apoptosis commitment in colorectal tumor cells.</text>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>We have studied caspase-3 activation by combined DNA damage induction and EGFR kinase inhibition in order to identify potential EGFR-mediated survival signals conferring resistance to apoptosis in human colorectal tumor cells.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="88" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="146" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="200" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>299</offset>
        <text>The onset of apoptosis was microscopically imaged with a newly developed caspase-3 substrate sensor based on EGFP and tHcred1, enabling us to monitor caspase-3 activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="372" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="449" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>565</offset>
        <text>Both optical approaches provide parameters quantitatively reporting the ratio between cleaved and uncleaved sensor, thereby facilitating the comparison of caspase-3 activation between different cells.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="720" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>766</offset>
        <text>Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="867" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="917" length="4"/>
          <text>EGFR</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17535976</id>
    <passage>
      <offset>0</offset>
      <text>Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.	Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation. In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone. PPARgamma activation selectively inhibited cell viability of non-small-cell lung cancer with little effect on small-cell lung cancer and normal lung cells. The cell death induced by PPARgamma activation presented apoptotic features of oligonucleosomal DNA fragmentation in A549 human non-small-cell lung cancer cell line. Reactive oxygen species (ROS) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists. POX RNA interference treatment blocked PPARgamma-induced ROS formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through ROS formation. The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions. The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via POX induction.</text>
      <sentence>
        <offset>0</offset>
        <text>Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor-gamma</infon>
          <location offset="20" length="48"/>
          <text>peroxisome proliferator-activated receptor-gamma</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proline oxidase</infon>
          <location offset="132" length="15"/>
          <text>proline oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>191</offset>
        <text>Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.</text>
      </sentence>
      <sentence>
        <offset>344</offset>
        <text>In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="407" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-(trans-methylimino-n-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1h-indene-2-carboxylic acid ethyl ester</infon>
          <location offset="486" length="100"/>
          <text>1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosiglitazone</infon>
          <location offset="603" length="13"/>
          <text>rosiglitazone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>618</offset>
        <text>PPARgamma activation selectively inhibited cell viability of non-small-cell lung cancer with little effect on small-cell lung cancer and normal lung cells.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="618" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>774</offset>
        <text>The cell death induced by PPARgamma activation presented apoptotic features of oligonucleosomal DNA fragmentation in A549 human non-small-cell lung cancer cell line.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="800" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>940</offset>
        <text>Reactive oxygen species (ROS) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ros</infon>
          <location offset="965" length="3"/>
          <text>ROS</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proline oxidase</infon>
          <location offset="1024" length="15"/>
          <text>proline oxidase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="1041" length="3"/>
          <text>POX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>POX RNA interference treatment blocked PPARgamma-induced ROS formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through ROS formation.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="1124" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1163" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ros</infon>
          <location offset="1181" length="3"/>
          <text>ROS</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="1229" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ros</infon>
          <location offset="1278" length="3"/>
          <text>ROS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1293</offset>
        <text>The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisphenol a diglycidyl ether</infon>
          <location offset="1351" length="28"/>
          <text>bisphenol A diglycidyl ether</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1425" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1477" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1505</offset>
        <text>The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via POX induction.</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1551" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ros</infon>
          <location offset="1649" length="3"/>
          <text>ROS</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="1667" length="3"/>
          <text>POX</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17599377</id>
    <passage>
      <offset>0</offset>
      <text>Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.	The aryl hydrocarbon receptor (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells. Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression. In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by TCDD was significantly inhibited. This was not accompanied by decreased nuclear AhR levels or decreased interaction of the AhR complex with the CYP1A1 gene promoter as determined in a chromatin immunoprecipitation assay. Hypoxia-induced loss of Ah-responsiveness was not associated with induction of hypoxia-inducible factor-1alpha or other factors that sequester the AhR nuclear translocation (Arnt) protein, and overexpression of Arnt under hypoxia did not restore Ah-responsiveness. The p65 subunit of NFkappaB which inhibits AhR-mediated transactivation was not induced by hypoxia and was primarily cytosolic in ZR-75 cells grown under hypoxic and normoxic conditions. In ZR-75 cells maintained under hypoxic conditions for 24 h, BRCA1 (an enhancer of AhR-mediated transactivation in breast cancer cells) was significantly decreased and this contributed to loss of Ah-responsiveness. In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by TCDD was significantly decreased. Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia. These results suggest that hypoxia rapidly induces protein(s) that inhibit Ah-responsiveness and these may be similar to constitutively expressed inhibitors of Ah-responsiveness (under normoxia) that are also inhibited by cycloheximide.</text>
      <sentence>
        <offset>0</offset>
        <text>Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aryl hydrocarbon receptor</infon>
          <location offset="39" length="25"/>
          <text>aryl hydrocarbon receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>The aryl hydrocarbon receptor (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aryl hydrocarbon receptor</infon>
          <location offset="112" length="25"/>
          <text>aryl hydrocarbon receptor</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="139" length="3"/>
          <text>AhR</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="160" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="179" length="2"/>
          <text>ER</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>219</offset>
        <text>Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,3,7,8-tetrachlorodibenzo-p-dioxin</infon>
          <location offset="234" length="35"/>
          <text>2,3,7,8-tetrachlorodibenzo-p-dioxin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="271" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a1</infon>
          <location offset="285" length="6"/>
          <text>CYP1A1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T9" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T10" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by TCDD was significantly inhibited.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="481" length="3"/>
          <text>AhR</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="507" length="4"/>
          <text>TCDD</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T14" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>541</offset>
        <text>This was not accompanied by decreased nuclear AhR levels or decreased interaction of the AhR complex with the CYP1A1 gene promoter as determined in a chromatin immunoprecipitation assay.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="587" length="3"/>
          <text>AhR</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="630" length="3"/>
          <text>AhR</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a1</infon>
          <location offset="651" length="6"/>
          <text>CYP1A1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>728</offset>
        <text>Hypoxia-induced loss of Ah-responsiveness was not associated with induction of hypoxia-inducible factor-1alpha or other factors that sequester the AhR nuclear translocation (Arnt) protein, and overexpression of Arnt under hypoxia did not restore Ah-responsiveness.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr translocation</infon>
          <location offset="875" length="25"/>
          <text>AhR translocation</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arnt) protein</infon>
          <location offset="902" length="13"/>
          <text>Arnt) protein</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arnt</infon>
          <location offset="939" length="4"/>
          <text>Arnt</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>993</offset>
        <text>The p65 subunit of NFkappaB which inhibits AhR-mediated transactivation was not induced by hypoxia and was primarily cytosolic in ZR-75 cells grown under hypoxic and normoxic conditions.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="997" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nfkappab</infon>
          <location offset="1012" length="8"/>
          <text>NFkappaB</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="1036" length="3"/>
          <text>AhR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1180</offset>
        <text>In ZR-75 cells maintained under hypoxic conditions for 24 h, BRCA1 (an enhancer of AhR-mediated transactivation in breast cancer cells) was significantly decreased and this contributed to loss of Ah-responsiveness.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">brca1</infon>
          <location offset="1241" length="5"/>
          <text>BRCA1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="1263" length="3"/>
          <text>AhR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1395</offset>
        <text>In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by TCDD was significantly decreased.</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">brca1</infon>
          <location offset="1433" length="5"/>
          <text>BRCA1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a1</infon>
          <location offset="1475" length="6"/>
          <text>CYP1A1</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="1485" length="4"/>
          <text>TCDD</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T37" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1519</offset>
        <text>Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="1551" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cycloheximide</infon>
          <location offset="1593" length="13"/>
          <text>cycloheximide</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a1</infon>
          <location offset="1624" length="6"/>
          <text>CYP1A1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T40" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1685</offset>
        <text>These results suggest that hypoxia rapidly induces protein(s) that inhibit Ah-responsiveness and these may be similar to constitutively expressed inhibitors of Ah-responsiveness (under normoxia) that are also inhibited by cycloheximide.</text>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cycloheximide</infon>
          <location offset="1907" length="13"/>
          <text>cycloheximide</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17620431</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.	With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy correlates with the modulation of desired/intended target in vivo. We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation. It has good oral exposure and inhibits angiogenesis and tumor growth in mice. Because bolus administration of the compound results in large differences in C(max) and C(trough), we investigated the effect of continuous infusion of a VEGFR inhibitor on tumor growth and angiogenesis. GW771806, which has similar enzyme and cellular profiles to GW786034, was used for these studies due to higher solubility requirements for infusion studies. Comparing the pharmacokinetics by two different routes of administration (bolus p.o. dosing and continuous infusion), we showed that the antitumor and antiangiogenic activity of VEGFR inhibitors is dependent on steady-state concentration of the compound above a threshold. The steady-state concentration required for these effects is consistent with the concentration required for the inhibition of VEGF-induced VEGFR2 phosphorylation in mouse lungs. Furthermore, the steady-state concentration of pazopanib determined from preclinical activity showed a strong correlation with the pharmacodynamic effects and antitumor activity in the phase I clinical trial.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pazopanib</infon>
          <location offset="69" length="9"/>
          <text>pazopanib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy correlates with the modulation of desired/intended target in vivo.</text>
      </sentence>
      <sentence>
        <offset>392</offset>
        <text>We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="450" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr</infon>
          <location offset="503" length="5"/>
          <text>VEGFR</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet-derived growth factor receptor</infon>
          <location offset="511" length="39"/>
          <text>platelet-derived growth factor receptor</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-kit tyrosine kinases</infon>
          <location offset="556" length="22"/>
          <text>c-Kit tyrosine kinases</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pazopanib</infon>
          <location offset="580" length="9"/>
          <text>pazopanib</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw786034</infon>
          <location offset="591" length="8"/>
          <text>GW786034</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="629" length="4"/>
          <text>VEGF</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T8" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T8" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T8" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>674</offset>
        <text>It has good oral exposure and inhibits angiogenesis and tumor growth in mice.</text>
      </sentence>
      <sentence>
        <offset>752</offset>
        <text>Because bolus administration of the compound results in large differences in C(max) and C(trough), we investigated the effect of continuous infusion of a VEGFR inhibitor on tumor growth and angiogenesis.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr</infon>
          <location offset="906" length="5"/>
          <text>VEGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>956</offset>
        <text>GW771806, which has similar enzyme and cellular profiles to GW786034, was used for these studies due to higher solubility requirements for infusion studies.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw771806</infon>
          <location offset="956" length="8"/>
          <text>GW771806</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw786034</infon>
          <location offset="1016" length="8"/>
          <text>GW786034</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1113</offset>
        <text>Comparing the pharmacokinetics by two different routes of administration (bolus p.o. dosing and continuous infusion), we showed that the antitumor and antiangiogenic activity of VEGFR inhibitors is dependent on steady-state concentration of the compound above a threshold.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr</infon>
          <location offset="1291" length="5"/>
          <text>VEGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1386</offset>
        <text>The steady-state concentration required for these effects is consistent with the concentration required for the inhibition of VEGF-induced VEGFR2 phosphorylation in mouse lungs.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1512" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr2</infon>
          <location offset="1525" length="6"/>
          <text>VEGFR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1564</offset>
        <text>Furthermore, the steady-state concentration of pazopanib determined from preclinical activity showed a strong correlation with the pharmacodynamic effects and antitumor activity in the phase I clinical trial.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pazopanib</infon>
          <location offset="1611" length="9"/>
          <text>pazopanib</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17626206</id>
    <passage>
      <offset>0</offset>
      <text>Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors.	An involvement of the transient receptor potential vanilloid (TRPV) 1 channel in the regulation of body temperature (T(b)) has not been established decisively. To provide decisive evidence for such an involvement and determine its mechanisms were the aims of the present study. We synthesized a new TRPV1 antagonist, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro. We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent. AMG0347-induced hyperthermia was brought about by one or both of the two major autonomic cold-defense effector mechanisms (<e2>kin vasoconstriction and/or thermogenesis), but it did not involve warmth-seeking behavior. The magnitude of the hyperthermic response depended on neither T(b) nor <e2>kin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors. AMG0347 was no more effective in causing hyperthermia when administered into the brain (intracerebroventricularly) or spinal cord (intrathecally) than when given systemically (intravenously), which indicates a peripheral site of action. We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests. We conclude that tonic activation of TRPV1 channels in the abdominal viscera by yet unidentified nonthermal factors inhibits skin vasoconstriction and thermogenesis, thus having a suppressive effect on T(b).</text>
      <sentence>
        <offset>0</offset>
        <text>Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transient receptor potential vanilloid-1 channels</infon>
          <location offset="25" length="49"/>
          <text>transient receptor potential vanilloid-1 channels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>149</offset>
        <text>An involvement of the transient receptor potential vanilloid (TRPV) 1 channel in the regulation of body temperature (T(b)) has not been established decisively.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv) 1</infon>
          <location offset="211" length="7"/>
          <text>TRPV) 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>To provide decisive evidence for such an involvement and determine its mechanisms were the aims of the present study.</text>
      </sentence>
      <sentence>
        <offset>427</offset>
        <text>We synthesized a new TRPV1 antagonist, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="466" length="7"/>
          <text>AMG0347</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(e)-n-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide</infon>
          <location offset="475" length="116"/>
          <text>(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>625</offset>
        <text>We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="806" length="7"/>
          <text>AMG0347</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv1</infon>
          <location offset="817" length="5"/>
          <text>TRPV1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>834</offset>
        <text>AMG0347-induced hyperthermia was brought about by one or both of the two major autonomic cold-defense effector mechanisms (<e2>kin vasoconstriction and/or thermogenesis), but it did not involve warmth-seeking behavior.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="834" length="7"/>
          <text>AMG0347</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1055</offset>
        <text>The magnitude of the hyperthermic response depended on neither T(b) nor <e2>kin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="1164" length="7"/>
          <text>AMG0347</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="1209" length="7"/>
          <text>AMG0347</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv1</infon>
          <location offset="1269" length="5"/>
          <text>TRPV1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1309</offset>
        <text>AMG0347 was no more effective in causing hyperthermia when administered into the brain (intracerebroventricularly) or spinal cord (intrathecally) than when given systemically (intravenously), which indicates a peripheral site of action.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="1309" length="7"/>
          <text>AMG0347</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1546</offset>
        <text>We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv1</infon>
          <location offset="1616" length="5"/>
          <text>TRPV1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amg0347</infon>
          <location offset="1705" length="7"/>
          <text>AMG0347</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1813</offset>
        <text>We conclude that tonic activation of TRPV1 channels in the abdominal viscera by yet unidentified nonthermal factors inhibits skin vasoconstriction and thermogenesis, thus having a suppressive effect on T(b).</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv1</infon>
          <location offset="1850" length="5"/>
          <text>TRPV1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17805244</id>
    <passage>
      <offset>0</offset>
      <text>Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.	The finding that activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component. The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma. Several lines of evidence from experiments using AD-related transgenic cellular and animal models have supported this hypothesis. The capacity of PPARgamma agonists to elicit anti-inflammatory, anti-amyloidogenic and insulin-sensitizing effects might account for their observed protective effects. Several clinical trials employing PPARgamma agonists have yielded promising results, and further trials are in preparation. Positive outcomes following PPARgamma administration have been obtained in animal models of other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis, both of which are associated with a considerable degree of neuroinflammation. Finally, activation of PPARgamma has been found to be protective in several models of multiple sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in patients with multiple sclerosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor-gamma</infon>
          <location offset="34" length="48"/>
          <text>peroxisome proliferator-activated receptor-gamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>101</offset>
        <text>The finding that activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor-gamma</infon>
          <location offset="132" length="48"/>
          <text>peroxisome proliferator-activated receptor-gamma</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="182" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>402</offset>
        <text>The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nsaids</infon>
          <location offset="416" length="6"/>
          <text>NSAIDs</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="539" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nsaid</infon>
          <location offset="594" length="5"/>
          <text>NSAID</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="632" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T10" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>643</offset>
        <text>Several lines of evidence from experiments using AD-related transgenic cellular and animal models have supported this hypothesis.</text>
      </sentence>
      <sentence>
        <offset>773</offset>
        <text>The capacity of PPARgamma agonists to elicit anti-inflammatory, anti-amyloidogenic and insulin-sensitizing effects might account for their observed protective effects.</text>
      </sentence>
      <sentence>
        <offset>941</offset>
        <text>Several clinical trials employing PPARgamma agonists have yielded promising results, and further trials are in preparation.</text>
      </sentence>
      <sentence>
        <offset>1065</offset>
        <text>Positive outcomes following PPARgamma administration have been obtained in animal models of other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis, both of which are associated with a considerable degree of neuroinflammation.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1093" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1334</offset>
        <text>Finally, activation of PPARgamma has been found to be protective in several models of multiple sclerosis.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1357" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1440</offset>
        <text>The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in patients with multiple sclerosis.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1545" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17875725</id>
    <passage>
      <offset>0</offset>
      <text>Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.	Doxorubicin is among the most effective and widely used anticancer drugs in the clinic. However, cardiotoxicity is one of the life-threatening side effects of doxorubicin-based therapy. Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity. The molecular basis for doxorubicin cardiotoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood. In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta). Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage. Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. The specific involvement of proteasome and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.</text>
      <sentence>
        <offset>0</offset>
        <text>Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">topoisomerase iibeta</infon>
          <location offset="0" length="20"/>
          <text>Topoisomerase IIbeta</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="72" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="117" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>130</offset>
        <text>Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="130" length="11"/>
          <text>Doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>218</offset>
        <text>However, cardiotoxicity is one of the life-threatening side effects of doxorubicin-based therapy.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="289" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>316</offset>
        <text>Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="316" length="11"/>
          <text>Dexrazoxane</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinecard</infon>
          <location offset="329" length="8"/>
          <text>Zinecard</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">icrf-187</infon>
          <location offset="353" length="8"/>
          <text>ICRF-187</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="421" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>449</offset>
        <text>The molecular basis for doxorubicin cardiotoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="473" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="535" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>582</offset>
        <text>In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="619" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="698" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camptothecin</infon>
          <location offset="719" length="12"/>
          <text>camptothecin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen peroxide</infon>
          <location offset="735" length="17"/>
          <text>hydrogen peroxide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>778</offset>
        <text>Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="778" length="11"/>
          <text>Doxorubicin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bortezomib</infon>
          <location offset="870" length="10"/>
          <text>bortezomib</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg132</infon>
          <location offset="885" length="5"/>
          <text>MG132</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">topoisomerase iibeta</infon>
          <location offset="1042" length="20"/>
          <text>topoisomerase IIbeta</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2beta</infon>
          <location offset="1064" length="8"/>
          <text>Top2beta</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T21" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T18" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1075</offset>
        <text>Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2</infon>
          <location offset="1116" length="4"/>
          <text>Top2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="1149" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2beta</infon>
          <location offset="1195" length="8"/>
          <text>Top2beta</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1239" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T27" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T29" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1271</offset>
        <text>Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="1306" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1330" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2beta</infon>
          <location offset="1391" length="8"/>
          <text>Top2beta</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2beta</infon>
          <location offset="1423" length="8"/>
          <text>Top2beta</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1435" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T36" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1463</offset>
        <text>The specific involvement of proteasome and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top2beta</infon>
          <location offset="1506" length="8"/>
          <text>Top2beta</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1518" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1611" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T41" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17938326</id>
    <passage>
      <offset>0</offset>
      <text>Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.	OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells. DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib. Immunofluorescence was employed to determine the cellular expression of ABCG2. The ABCG2 expression in ARO and WRO cell lines was analyzed by Western blot analysis. Inactivation of EGFR kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence. A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of doxorubicin. Colony formation assays were performed to determine the effect of gefitinib on thyroid cancer cell survival in response to gefitinib, doxorubicin, or the combination of both drugs. RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines. Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA. The addition of gefitinib increases doxorubicin-induced cell death in thyroid cancer cells as measured by colony formation assay. CONCLUSIONS: Epidermal growth factor receptor regulates the function of the drug transporter ABCG2/BCRP1 and correlates with ABCG2 protein expression levels. Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin. The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer. Use of this combination treatment of gefitinib and doxorubicin may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.</text>
      <sentence>
        <offset>0</offset>
        <text>Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="0" length="9"/>
          <text>Gefitinib</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="43" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="71" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T1" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">breast cancer resistance protein abcg2/brcp1</infon>
          <location offset="155" length="44"/>
          <text>breast cancer resistance protein ABCG2/BRCP1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="220" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="254" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="302" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin hydrochloride</infon>
          <location offset="376" length="25"/>
          <text>doxorubicin hydrochloride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>457</offset>
        <text>DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="605" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="626" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="679" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>690</offset>
        <text>Immunofluorescence was employed to determine the cellular expression of ABCG2.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="762" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>769</offset>
        <text>The ABCG2 expression in ARO and WRO cell lines was analyzed by Western blot analysis.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="773" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>855</offset>
        <text>Inactivation of EGFR kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="871" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="886" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>958</offset>
        <text>A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of doxorubicin.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1086" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1130" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T21" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1143</offset>
        <text>Colony formation assays were performed to determine the effect of gefitinib on thyroid cancer cell survival in response to gefitinib, doxorubicin, or the combination of both drugs.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="1209" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="1266" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1277" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1324</offset>
        <text>RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1347" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="1371" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1413" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1506" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T27" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T27" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1558</offset>
        <text>Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1601" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1651" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1684" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T33" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1728</offset>
        <text>The addition of gefitinib increases doxorubicin-induced cell death in thyroid cancer cells as measured by colony formation assay.</text>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="1744" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1764" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1858</offset>
        <text>CONCLUSIONS: Epidermal growth factor receptor regulates the function of the drug transporter ABCG2/BCRP1 and correlates with ABCG2 protein expression levels.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="1871" length="32"/>
          <text>Epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1983" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2016</offset>
        <text>Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.</text>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="2036" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="2051" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="2097" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="2189" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T43" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T46" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2202</offset>
        <text>The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.</text>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="2220" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="2269" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T48" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2400</offset>
        <text>Use of this combination treatment of gefitinib and doxorubicin may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.</text>
        <annotation id="T51">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gefitinib</infon>
          <location offset="2437" length="9"/>
          <text>gefitinib</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="2451" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18026124</id>
    <passage>
      <offset>0</offset>
      <text>Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.	Ischaemia-reperfusion (I/R) is a pivotal mechanism of organ injury during stroke, myocardial infarction, organ transplantation and vascular surgeries. Ischaemic preconditioning (IPC) is a potent endogenous form of tissue protection against I/R injury. On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms. However, there is evidence suggesting that endocannabinoids are overproduced during various forms of I/R, such as myocardial infarction or whole body I/R associated with circulatory shock, and may contribute to the cardiovascular depressive state associated with these pathologies. Previous studies using synthetic CB1 receptor agonists or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models. In contrast, several follow-up reports have shown protection afforded by CB1 receptor antagonists, but not agonists. Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage. This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.</text>
      <sentence>
        <offset>0</offset>
        <text>Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">endocannabinoids</infon>
          <location offset="0" length="16"/>
          <text>Endocannabinoids</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cannabinoid receptors</infon>
          <location offset="21" length="21"/>
          <text>cannabinoid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>Ischaemia-reperfusion (I/R) is a pivotal mechanism of organ injury during stroke, myocardial infarction, organ transplantation and vascular surgeries.</text>
      </sentence>
      <sentence>
        <offset>247</offset>
        <text>Ischaemic preconditioning (IPC) is a potent endogenous form of tissue protection against I/R injury.</text>
      </sentence>
      <sentence>
        <offset>348</offset>
        <text>On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">endocannabinoids</infon>
          <location offset="365" length="16"/>
          <text>endocannabinoids</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb1</infon>
          <location offset="456" length="3"/>
          <text>CB1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="460" length="3"/>
          <text>CB2</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T4" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>512</offset>
        <text>However, there is evidence suggesting that endocannabinoids are overproduced during various forms of I/R, such as myocardial infarction or whole body I/R associated with circulatory shock, and may contribute to the cardiovascular depressive state associated with these pathologies.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">endocannabinoids</infon>
          <location offset="555" length="16"/>
          <text>endocannabinoids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>794</offset>
        <text>Previous studies using synthetic CB1 receptor agonists or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">synthetic cb1 receptor agonists</infon>
          <location offset="817" length="31"/>
          <text>synthetic CB1 receptor agonists</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb1</infon>
          <location offset="879" length="3"/>
          <text>CB1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>In contrast, several follow-up reports have shown protection afforded by CB1 receptor antagonists, but not agonists.</text>
      </sentence>
      <sentence>
        <offset>1084</offset>
        <text>Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cb2 receptor agonists</infon>
          <location offset="1125" length="21"/>
          <text>CB2 receptor agonists</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="1207" length="3"/>
          <text>CB2</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T14" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1621</offset>
        <text>This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">endocannabinoids</infon>
          <location offset="1665" length="16"/>
          <text>endocannabinoids</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb receptors</infon>
          <location offset="1686" length="12"/>
          <text>CB receptors</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cb2 receptor agonists</infon>
          <location offset="1883" length="21"/>
          <text>CB2 receptor agonists</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18155663</id>
    <passage>
      <offset>0</offset>
      <text>PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.	We explored the in vitro effects of Rosiglitazone (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure. We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation. It rather involved, through a PPARgamma-dependent mechanism, a reduction of iNOS overexpressed in lipotoxic islets. This reduction likely led to the restoration of ATP level and insulin secretion as well as the decrease in apoptosis. More interestingly, we also demonstrated that RZG beneficial effects involved PPARgamma-independent mechanisms. RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression. It also increased UCP2 expression that seemed to display antioxidant action in this model. Thus, RZG did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.</text>
      <sentence>
        <offset>0</offset>
        <text>PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosiglitazone</infon>
          <location offset="48" length="13"/>
          <text>rosiglitazone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>100</offset>
        <text>We explored the in vitro effects of Rosiglitazone (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosiglitazone</infon>
          <location offset="136" length="13"/>
          <text>Rosiglitazone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rzg</infon>
          <location offset="151" length="3"/>
          <text>RZG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>262</offset>
        <text>We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rzg</infon>
          <location offset="283" length="3"/>
          <text>RZG</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdx-1</infon>
          <location offset="355" length="5"/>
          <text>PDX-1</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="364" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>389</offset>
        <text>It rather involved, through a PPARgamma-dependent mechanism, a reduction of iNOS overexpressed in lipotoxic islets.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="465" length="4"/>
          <text>iNOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>505</offset>
        <text>This reduction likely led to the restoration of ATP level and insulin secretion as well as the decrease in apoptosis.</text>
      </sentence>
      <sentence>
        <offset>623</offset>
        <text>More interestingly, we also demonstrated that RZG beneficial effects involved PPARgamma-independent mechanisms.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rzg</infon>
          <location offset="669" length="3"/>
          <text>RZG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>735</offset>
        <text>RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rzg</infon>
          <location offset="735" length="3"/>
          <text>RZG</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpx</infon>
          <location offset="819" length="3"/>
          <text>GPx</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sod</infon>
          <location offset="827" length="3"/>
          <text>SOD</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>843</offset>
        <text>It also increased UCP2 expression that seemed to display antioxidant action in this model.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ucp2</infon>
          <location offset="861" length="4"/>
          <text>UCP2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>934</offset>
        <text>Thus, RZG did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rzg</infon>
          <location offset="940" length="3"/>
          <text>RZG</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18165569</id>
    <passage>
      <offset>0</offset>
      <text>The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.	BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in. human liver microsomes in vitro with K(i) values of 5 microM (1.4 mg/L) and 13 microM (3.6 mg/L), respectively. We investigated the effect of a 50 h continuous epidural infusion of ropivacaine 2 mg/mL at a rate of 14 mL/h on CYP2D6 activity. METHODS: Nineteen patients (41-85 yr) undergoing hip or knee replacement, all extensive metabolizers with respect to CYP2D6 activity, were included. Medications known to inhibit or be metabolized by CYP2D6, or known to be strong inhibitors/inducers of CYP1A2 or CYP3A4 were not allowed. Patients received 10 mg debrisoquine (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion. The metabolic ratio (MR) for debrisoquine hydroxylation was calculated as the amount of debrisoquine/amount of 4-OH-debrisoquine excreted in 0-10 h urine. RESULTS: The median (range) of MR before and after ropivacaine were 0.54 (0.1-3.4) and 1.79 (0.3-6.7), respectively. The Hodges Lehman estimate of the ratio MR after/MR before ropivacaine was 2.2 with a 95% confidence interval 1.9-2.7 (P &lt; 0.001). CONCLUSION: A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation. However, since none of the patients was converted into a functional poor metabolizer (MR &gt;12.6), the effect on the metabolism of other drugs metabolized by CYP2D6 is unlikely to be of major clinical importance.</text>
      <sentence>
        <offset>0</offset>
        <text>The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="47" length="11"/>
          <text>ropivacaine</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="62" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>79</offset>
        <text>BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in. human liver microsomes in vitro with K(i) values of 5 microM (1.4 mg/L) and 13 microM (3.6 mg/L), respectively.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="91" length="11"/>
          <text>Ropivacaine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pipecoloxylidide</infon>
          <location offset="131" length="16"/>
          <text>pipecoloxylidide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="157" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T2" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T3" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>We investigated the effect of a 50 h continuous epidural infusion of ropivacaine 2 mg/mL at a rate of 14 mL/h on CYP2D6 activity.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="349" length="11"/>
          <text>ropivacaine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="393" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>410</offset>
        <text>METHODS: Nineteen patients (41-85 yr) undergoing hip or knee replacement, all extensive metabolizers with respect to CYP2D6 activity, were included.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="527" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>559</offset>
        <text>Medications known to inhibit or be metabolized by CYP2D6, or known to be strong inhibitors/inducers of CYP1A2 or CYP3A4 were not allowed.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="609" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="662" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="672" length="6"/>
          <text>CYP3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>697</offset>
        <text>Patients received 10 mg debrisoquine (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">debrisoquine</infon>
          <location offset="721" length="12"/>
          <text>debrisoquine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="748" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>814</offset>
        <text>The metabolic ratio (MR) for debrisoquine hydroxylation was calculated as the amount of debrisoquine/amount of 4-OH-debrisoquine excreted in 0-10 h urine.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">debrisoquine</infon>
          <location offset="843" length="12"/>
          <text>debrisoquine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">debrisoquine</infon>
          <location offset="902" length="12"/>
          <text>debrisoquine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-oh-debrisoquine</infon>
          <location offset="925" length="17"/>
          <text>4-OH-debrisoquine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>969</offset>
        <text>RESULTS: The median (range) of MR before and after ropivacaine were 0.54 (0.1-3.4) and 1.79 (0.3-6.7), respectively.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="1020" length="11"/>
          <text>ropivacaine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1086</offset>
        <text>The Hodges Lehman estimate of the ratio MR after/MR before ropivacaine was 2.2 with a 95% confidence interval 1.9-2.7 (P &lt; 0.001).</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="1145" length="11"/>
          <text>ropivacaine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1217</offset>
        <text>CONCLUSION: A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ropivacaine</infon>
          <location offset="1263" length="11"/>
          <text>ropivacaine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="1284" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">debrisoquine</infon>
          <location offset="1389" length="12"/>
          <text>debrisoquine</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T20" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T18" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1417</offset>
        <text>However, since none of the patients was converted into a functional poor metabolizer (MR &gt;12.6), the effect on the metabolism of other drugs metabolized by CYP2D6 is unlikely to be of major clinical importance.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="1573" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18202009</id>
    <passage>
      <offset>0</offset>
      <text>CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.	Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma. The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML. We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells. In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration. This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha. Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system. MSC coculture protected KBM-5 cells from imatinib-induced cell death. These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267. Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.</text>
      <sentence>
        <offset>0</offset>
        <text>CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="0" length="5"/>
          <text>CXCR4</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="23" length="8"/>
          <text>imatinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T1" role="head"/>
          <node refid="T0" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>158</offset>
        <text>Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl tyrosine kinase</infon>
          <location offset="231" length="23"/>
          <text>Bcr-Abl tyrosine kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>328</offset>
        <text>The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="392" length="5"/>
          <text>CXCR4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="518" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inno-406</infon>
          <location offset="530" length="8"/>
          <text>INNO-406</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="552" length="5"/>
          <text>CXCR4</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T9" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T10" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>743</offset>
        <text>In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="767" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inno-406</infon>
          <location offset="777" length="8"/>
          <text>INNO-406</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ifn-alpha</infon>
          <location offset="790" length="9"/>
          <text>IFN-alpha</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="810" length="5"/>
          <text>CXCR4</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T14" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T12" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>842</offset>
        <text>This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="859" length="5"/>
          <text>CXCR4</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="957" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ifn-alpha</infon>
          <location offset="969" length="9"/>
          <text>IFN-alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T17" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>980</offset>
        <text>Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="980" length="8"/>
          <text>Imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1112</offset>
        <text>MSC coculture protected KBM-5 cells from imatinib-induced cell death.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1153" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1182</offset>
        <text>These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amd3465</infon>
          <location offset="1249" length="7"/>
          <text>AMD3465</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">qlt0267</infon>
          <location offset="1299" length="7"/>
          <text>QLT0267</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcr4</infon>
          <location offset="1369" length="5"/>
          <text>CXCR4</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1378" length="8"/>
          <text>imatinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T27" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18234154</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).	Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype. Thus, the development of effective transporter inhibitors could be of value to cancer treatment. CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor. We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors. CBT-1 completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM. Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells. CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (&lt;1 microM) stimulated Pgp-mediated ATP hydrolysis. In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated calcein transport. CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport. Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay. CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed. Further clinical studies with CBT-1 are warranted.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="14" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="30" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">multidrug resistance-associated protein</infon>
          <location offset="42" length="39"/>
          <text>multidrug resistance-associated protein</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">1</infon>
          <location offset="82" length="1"/>
          <text>1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcc1</infon>
          <location offset="85" length="5"/>
          <text>ABCC1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1((r))</infon>
          <location offset="149" length="10"/>
          <text>CBT-1((R))</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="239" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="255" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">multidrug resistance-associated protein</infon>
          <location offset="261" length="39"/>
          <text>multidrug resistance-associated protein</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="302" length="4"/>
          <text>MRP1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="312" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>366</offset>
        <text>Thus, the development of effective transporter inhibitors could be of value to cancer treatment.</text>
      </sentence>
      <sentence>
        <offset>463</offset>
        <text>CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="463" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="541" length="3"/>
          <text>Pgp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>556</offset>
        <text>We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abc transporters</infon>
          <location offset="611" length="16"/>
          <text>ABC transporters</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="662" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="667" length="4"/>
          <text>MRP1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="676" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>727</offset>
        <text>CBT-1 completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="727" length="5"/>
          <text>CBT-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>836</offset>
        <text>Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="879" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinblastine</infon>
          <location offset="906" length="11"/>
          <text>vinblastine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="919" length="10"/>
          <text>paclitaxel</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>968</offset>
        <text>CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (&lt;1 microM) stimulated Pgp-mediated ATP hydrolysis.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="968" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="1021" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1082" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="1111" length="3"/>
          <text>Pgp</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1140</offset>
        <text>In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated calcein transport.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1180" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="1218" length="4"/>
          <text>MRP1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T33" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1251</offset>
        <text>CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1251" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="1307" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1348</offset>
        <text>Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.</text>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1364" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1420" length="5"/>
          <text>CBT-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1524</offset>
        <text>CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.</text>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1524" length="5"/>
          <text>CBT-1</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abc transporters</infon>
          <location offset="1553" length="16"/>
          <text>ABC transporters</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="1570" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="1578" length="4"/>
          <text>MRP1</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="1655" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrp1</infon>
          <location offset="1666" length="4"/>
          <text>MRP1</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T42" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T42" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1695</offset>
        <text>Further clinical studies with CBT-1 are warranted.</text>
        <annotation id="T49">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cbt-1</infon>
          <location offset="1725" length="5"/>
          <text>CBT-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18337476</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.	Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats. We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR). The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to NPSR in the nanomolar range. The antagonistic activity of SHA 68 seems to be specific because it does not affect signaling at 14 unrelated G protein-coupled receptors. Analysis of pharmacokinetic parameters of SHA 68 demonstrates that the compound reaches pharmacologically relevant levels in plasma and brain after i.p. administration. Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior. Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="155" length="6"/>
          <text>SHA 68</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuropeptide s receptor</infon>
          <location offset="194" length="23"/>
          <text>neuropeptide S receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T1" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>219</offset>
        <text>Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuropeptide s</infon>
          <location offset="219" length="14"/>
          <text>Neuropeptide S</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nps</infon>
          <location offset="235" length="3"/>
          <text>NPS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>399</offset>
        <text>We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 66</infon>
          <location offset="477" length="6"/>
          <text>SHA 66</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="573" length="6"/>
          <text>SHA 68</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nps</infon>
          <location offset="752" length="3"/>
          <text>NPS</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npsr</infon>
          <location offset="766" length="4"/>
          <text>NPSR</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T5" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T7" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>773</offset>
        <text>The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to NPSR in the nanomolar range.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nps</infon>
          <location offset="793" length="3"/>
          <text>NPS</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="828" length="6"/>
          <text>SHA 68</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npsr</infon>
          <location offset="865" length="4"/>
          <text>NPSR</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>The antagonistic activity of SHA 68 seems to be specific because it does not affect signaling at 14 unrelated G protein-coupled receptors.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="923" length="6"/>
          <text>SHA 68</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1033</offset>
        <text>Analysis of pharmacokinetic parameters of SHA 68 demonstrates that the compound reaches pharmacologically relevant levels in plasma and brain after i.p. administration.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="1075" length="6"/>
          <text>SHA 68</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1202</offset>
        <text>Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="1244" length="6"/>
          <text>SHA 68</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nps</infon>
          <location offset="1297" length="3"/>
          <text>NPS</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T17" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1375</offset>
        <text>Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sha 68</infon>
          <location offset="1386" length="6"/>
          <text>SHA 68</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nps</infon>
          <location offset="1494" length="3"/>
          <text>NPS</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T20" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18341639</id>
    <passage>
      <offset>0</offset>
      <text>Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.	FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis. Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level. We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+). All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact. FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004). There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells. Synergistic cytotoxicity of lestaurtinib plus cytarabine was demonstrated in all three groups. These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.</text>
      <sentence>
        <offset>0</offset>
        <text>Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tyrosine kinase domain mutation flt3</infon>
          <location offset="43" length="39"/>
          <text>tyrosine kinase domain mutation FLT3</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lestaurtinib</infon>
          <location offset="105" length="12"/>
          <text>lestaurtinib</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3 internal tandem duplication</infon>
          <location offset="136" length="32"/>
          <text>FLT3 internal tandem duplication</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>170</offset>
        <text>FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3 tyrosine kinase domain mutations</infon>
          <location offset="170" length="37"/>
          <text>FLT3 tyrosine kinase domain mutations</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3 internal tandem duplications</infon>
          <location offset="304" length="33"/>
          <text>FLT3 internal tandem duplications</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>378</offset>
        <text>Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flt3 inhibitors</infon>
          <location offset="450" length="15"/>
          <text>FLT3 inhibitors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>604</offset>
        <text>We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytarabine</infon>
          <location offset="639" length="10"/>
          <text>cytarabine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lestaurtinib</infon>
          <location offset="673" length="12"/>
          <text>lestaurtinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>821</offset>
        <text>All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytarabine</infon>
          <location offset="893" length="10"/>
          <text>cytarabine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytarabine</infon>
          <location offset="960" length="10"/>
          <text>cytarabine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1040</offset>
        <text>FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lestaurtinib</infon>
          <location offset="1085" length="12"/>
          <text>lestaurtinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells.</text>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lestaurtinib</infon>
          <location offset="1223" length="12"/>
          <text>lestaurtinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1289</offset>
        <text>Synergistic cytotoxicity of lestaurtinib plus cytarabine was demonstrated in all three groups.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lestaurtinib</infon>
          <location offset="1317" length="12"/>
          <text>lestaurtinib</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytarabine</infon>
          <location offset="1335" length="10"/>
          <text>cytarabine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1384</offset>
        <text>These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.</text>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flt3 inhibitors</infon>
          <location offset="1513" length="15"/>
          <text>FLT3 inhibitors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18348297</id>
    <passage>
      <offset>0</offset>
      <text>Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.	BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome. To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome. METHODS: In an open-label prospective study, 26 men with recurrent or locally advanced prostate cancer were treated with leuprolide for 12 months. Outcomes included changes in blood pressure, body composition, lipids, adipocytokines, and C-reactive protein. RESULTS: The mean weight, body mass index, and waist circumference increased significantly from baseline to Month 12 (P &lt; .001 for each comparison). Fat mass increased by 11.2% +/- 1.5% (P &lt; .001) and the percentage lean body mass decreased by 3.6% +/- 0.5% (P &lt; .001). The total abdominal fat area increased by 16.5% +/- 2.6% (P &lt; .001), with the accumulation of subcutaneous fat accounting for 94% of the observed increase. The waist-to-hip ratio and blood pressure did not change significantly. Serum high-density lipoprotein (HDL) cholesterol concentrations increased significantly (P = .002). Serum adiponectin levels increased by 36.4 +/- 5.9% from baseline to Month 3 and remained significantly elevated through Month 12 (P &lt; .001). Resistin and C-reactive protein levels did not change significantly. CONCLUSIONS: The term metabolic syndrome does not appear to adequately describe the effects of GnRH agonists in men with prostate cancer. In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.</text>
      <sentence>
        <offset>0</offset>
        <text>Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gonadotropin-releasing hormone agonist</infon>
          <location offset="25" length="38"/>
          <text>gonadotropin-releasing hormone agonist</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>142</offset>
        <text>BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gonadotropin-releasing hormone</infon>
          <location offset="183" length="30"/>
          <text>gonadotropin-releasing hormone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gnrh) agonists</infon>
          <location offset="215" length="14"/>
          <text>GnRH) agonists</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>357</offset>
        <text>To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gnrh agonists</infon>
          <location offset="432" length="13"/>
          <text>GnRH agonists</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>493</offset>
        <text>METHODS: In an open-label prospective study, 26 men with recurrent or locally advanced prostate cancer were treated with leuprolide for 12 months.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leuprolide</infon>
          <location offset="614" length="10"/>
          <text>leuprolide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>640</offset>
        <text>Outcomes included changes in blood pressure, body composition, lipids, adipocytokines, and C-reactive protein.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adipocytokines</infon>
          <location offset="711" length="14"/>
          <text>adipocytokines</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-reactive protein</infon>
          <location offset="731" length="18"/>
          <text>C-reactive protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>751</offset>
        <text>RESULTS: The mean weight, body mass index, and waist circumference increased significantly from baseline to Month 12 (P &lt; .001 for each comparison).</text>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>Fat mass increased by 11.2% +/- 1.5% (P &lt; .001) and the percentage lean body mass decreased by 3.6% +/- 0.5% (P &lt; .001).</text>
      </sentence>
      <sentence>
        <offset>1021</offset>
        <text>The total abdominal fat area increased by 16.5% +/- 2.6% (P &lt; .001), with the accumulation of subcutaneous fat accounting for 94% of the observed increase.</text>
      </sentence>
      <sentence>
        <offset>1177</offset>
        <text>The waist-to-hip ratio and blood pressure did not change significantly.</text>
      </sentence>
      <sentence>
        <offset>1249</offset>
        <text>Serum high-density lipoprotein (HDL) cholesterol concentrations increased significantly (P = .002).</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">high-density lipoprotein</infon>
          <location offset="1255" length="24"/>
          <text>high-density lipoprotein</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hdl) cholesterol</infon>
          <location offset="1281" length="16"/>
          <text>HDL) cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>Serum adiponectin levels increased by 36.4 +/- 5.9% from baseline to Month 3 and remained significantly elevated through Month 12 (P &lt; .001).</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="1355" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1491</offset>
        <text>Resistin and C-reactive protein levels did not change significantly.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">resistin</infon>
          <location offset="1491" length="8"/>
          <text>Resistin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-reactive protein</infon>
          <location offset="1504" length="18"/>
          <text>C-reactive protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1560</offset>
        <text>CONCLUSIONS: The term metabolic syndrome does not appear to adequately describe the effects of GnRH agonists in men with prostate cancer.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gnrh agonists</infon>
          <location offset="1655" length="13"/>
          <text>GnRH agonists</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1698</offset>
        <text>In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gnrh agonists</infon>
          <location offset="1737" length="13"/>
          <text>GnRH agonists</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hdl cholesterol</infon>
          <location offset="1783" length="15"/>
          <text>HDL cholesterol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="1804" length="11"/>
          <text>adiponectin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-reactive protein</infon>
          <location offset="1877" length="18"/>
          <text>C-reactive protein</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18426370</id>
    <passage>
      <offset>0</offset>
      <text>Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.	Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P &lt; .001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P &lt; .001) largely explained this observation.</text>
      <sentence>
        <offset>0</offset>
        <text>Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenofovir</infon>
          <location offset="90" length="9"/>
          <text>tenofovir</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>101</offset>
        <text>Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P &lt; .001), despite elevated and stable rates of tenofovir use.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenofovir</infon>
          <location offset="403" length="9"/>
          <text>tenofovir</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>418</offset>
        <text>A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P &lt; .001) largely explained this observation.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">didanosine</infon>
          <location offset="465" length="10"/>
          <text>didanosine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18445086</id>
    <passage>
      <offset>0</offset>
      <text>MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.	The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage. PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies. The aberrant function of PML/RARalpha, together with the constitutive activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK/ERK) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes. The role of the MEK/ERK pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific MEK inhibitors. The blockade of MEK/ERK pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction. To our knowledge, this is the first report to show that PML/RARalpha was suppressed by MEK/ERK inhibition, through a mechanism dependent on caspase activation. ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors. Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of MEK/ERK inhibitors as an efficient therapeutic strategy for this haematological malignancy.</text>
      <sentence>
        <offset>0</offset>
        <text>MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="73" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">promyelocytic leukaemia/retinoic acid receptor alpha</infon>
          <location offset="263" length="52"/>
          <text>promyelocytic leukaemia/retinoic acid receptor alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>410</offset>
        <text>PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="410" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinoic acid</infon>
          <location offset="447" length="23"/>
          <text>all-trans-retinoic acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atra</infon>
          <location offset="472" length="4"/>
          <text>ATRA</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T10" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>558</offset>
        <text>The aberrant function of PML/RARalpha, together with the constitutive activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK/ERK) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="583" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>The role of the MEK/ERK pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific MEK inhibitors.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="888" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1015</offset>
        <text>The blockade of MEK/ERK pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="1092" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1161</offset>
        <text>To our knowledge, this is the first report to show that PML/RARalpha was suppressed by MEK/ERK inhibition, through a mechanism dependent on caspase activation.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="1217" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1321</offset>
        <text>ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atra</infon>
          <location offset="1321" length="4"/>
          <text>ATRA</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pml/raralpha</infon>
          <location offset="1384" length="12"/>
          <text>PML/RARalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1474</offset>
        <text>Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of MEK/ERK inhibitors as an efficient therapeutic strategy for this haematological malignancy.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18497344</id>
    <passage>
      <offset>0</offset>
      <text>The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the endometrial transcriptome in the window of implantation.	The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the endometrial transcriptome. Oocyte donors underwent endometrial biopsy during the implantation window of the nonstimulated cycle and following ovarian stimulation with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist but no luteal progesterone supplementation (n = 4). Microarray analysis showed 142 genes to be significantly upregulated and 98 significantly downregulated. Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6. Also upregulated were genes inhibited by progesterone, such as insulin-like growth factor binding protein 5. In conclusion, ovarian stimulation with follicle-stimulating hormone and gonadotropin-releasing hormone antagonist dysregulates the expression of many genes involved in cell adhesion, T-cell receptor signaling, and regulation of signal transduction. These data suggest that dysregulation of the endometrial transcriptome in the stimulated cycle is not fully attributable to supraphysiological sex steroid levels at the folliculo-luteal transition.</text>
      <sentence>
        <offset>0</offset>
        <text>The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the endometrial transcriptome in the window of implantation.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">recombinant fsh</infon>
          <location offset="39" length="15"/>
          <text>recombinant FSH</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gnrh antagonist</infon>
          <location offset="75" length="15"/>
          <text>GnRH antagonist</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>155</offset>
        <text>The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the endometrial transcriptome.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">follicle-stimulating hormone</infon>
          <location offset="270" length="28"/>
          <text>follicle-stimulating hormone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gonadotropin-releasing hormone antagonist</infon>
          <location offset="319" length="41"/>
          <text>gonadotropin-releasing hormone antagonist</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>Oocyte donors underwent endometrial biopsy during the implantation window of the nonstimulated cycle and following ovarian stimulation with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist but no luteal progesterone supplementation (n = 4).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">follicle-stimulating hormone</infon>
          <location offset="547" length="28"/>
          <text>follicle-stimulating hormone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gonadotropin-releasing hormone antagonist</infon>
          <location offset="580" length="41"/>
          <text>gonadotropin-releasing hormone antagonist</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="636" length="12"/>
          <text>progesterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>674</offset>
        <text>Microarray analysis showed 142 genes to be significantly upregulated and 98 significantly downregulated.</text>
      </sentence>
      <sentence>
        <offset>779</offset>
        <text>Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dickkopf steroidogenic acute regulatory protein</infon>
          <location offset="875" length="56"/>
          <text>Dickkopf steroidogenic acute regulatory protein</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">homeobox c6</infon>
          <location offset="937" length="11"/>
          <text>homeobox C6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>950</offset>
        <text>Also upregulated were genes inhibited by progesterone, such as insulin-like growth factor binding protein 5.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="991" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor binding protein 5</infon>
          <location offset="1013" length="44"/>
          <text>insulin-like growth factor binding protein 5</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1059</offset>
        <text>In conclusion, ovarian stimulation with follicle-stimulating hormone and gonadotropin-releasing hormone antagonist dysregulates the expression of many genes involved in cell adhesion, T-cell receptor signaling, and regulation of signal transduction.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">follicle-stimulating hormone</infon>
          <location offset="1099" length="28"/>
          <text>follicle-stimulating hormone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gonadotropin-releasing hormone antagonist</infon>
          <location offset="1132" length="41"/>
          <text>gonadotropin-releasing hormone antagonist</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1309</offset>
        <text>These data suggest that dysregulation of the endometrial transcriptome in the stimulated cycle is not fully attributable to supraphysiological sex steroid levels at the folliculo-luteal transition.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18524848</id>
    <passage>
      <offset>0</offset>
      <text>Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.	Mantle cell lymphoma (MCL) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years. Therefore, a better understanding of the underlying mechanisms that regulate MCL proliferation/survival is needed to develop an effective therapy. Because sonic hedgehog (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken. Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients. Perturbation of this signaling in the presence of exogenous Shh/cyclopamine significantly (P &lt; 0.001) influenced the proliferation of JVM2 MCL cells. Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P &lt; 0.001) decreased proliferation of the MCL cells but also significantly (P &lt; 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin. Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in MCL. Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of MCL, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for MCL.</text>
      <sentence>
        <offset>0</offset>
        <text>Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.</text>
        <annotation id="T0">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sonic</infon>
          <location offset="13" length="5"/>
          <text>sonic</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>109</offset>
        <text>Mantle cell lymphoma (MCL) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years.</text>
      </sentence>
      <sentence>
        <offset>248</offset>
        <text>Therefore, a better understanding of the underlying mechanisms that regulate MCL proliferation/survival is needed to develop an effective therapy.</text>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>Because sonic hedgehog (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sonic hedgehog</infon>
          <location offset="403" length="14"/>
          <text>sonic hedgehog</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>596</offset>
        <text>Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ptch</infon>
          <location offset="675" length="4"/>
          <text>PTCH</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="684" length="3"/>
          <text>SMO</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli1</infon>
          <location offset="703" length="4"/>
          <text>GLI1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli2</infon>
          <location offset="712" length="4"/>
          <text>GLI2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>826</offset>
        <text>Perturbation of this signaling in the presence of exogenous Shh/cyclopamine significantly (P &lt; 0.001) influenced the proliferation of JVM2 MCL cells.</text>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P &lt; 0.001) decreased proliferation of the MCL cells but also significantly (P &lt; 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="1008" length="3"/>
          <text>GLI</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1246" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T16" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in MCL.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="1284" length="3"/>
          <text>GLI</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="1298" length="9"/>
          <text>cyclin D1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="1312" length="4"/>
          <text>BCL2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="1398" length="3"/>
          <text>GLI</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1410</offset>
        <text>Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of MCL, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for MCL.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="1534" length="3"/>
          <text>GLI</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18544460</id>
    <passage>
      <offset>0</offset>
      <text>Update on novel therapeutic agents for cervical cancer.	Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months. Because of the minimal degree of success with cytotoxic therapies and the poor prognosis of patients with this disease, interest has increased in targeted therapeutics for the treatment of cervical cancer. In recent years, significant improvements in our understanding of the altered molecular events in tumor cells have led to the discovery of new targets and agents for clinical testing. Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis. Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer. In addition, VEGF receptor tyrosine kinase inhibitors, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials. In this review, we discuss potential molecular targets and novel therapeutic strategies that are being investigated for the treatment of cervical cancer.</text>
      <sentence>
        <offset>0</offset>
        <text>Update on novel therapeutic agents for cervical cancer.</text>
      </sentence>
      <sentence>
        <offset>56</offset>
        <text>Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited.</text>
      </sentence>
      <sentence>
        <offset>148</offset>
        <text>Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="148" length="9"/>
          <text>Cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>329</offset>
        <text>Because of the minimal degree of success with cytotoxic therapies and the poor prognosis of patients with this disease, interest has increased in targeted therapeutics for the treatment of cervical cancer.</text>
      </sentence>
      <sentence>
        <offset>535</offset>
        <text>In recent years, significant improvements in our understanding of the altered molecular events in tumor cells have led to the discovery of new targets and agents for clinical testing.</text>
      </sentence>
      <sentence>
        <offset>719</offset>
        <text>Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="754" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="788" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="802" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="838" length="4"/>
          <text>VEGF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>923</offset>
        <text>Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cetuximab</infon>
          <location offset="950" length="9"/>
          <text>cetuximab</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="975" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bevacizumab</infon>
          <location offset="985" length="11"/>
          <text>bevacizumab</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1015" length="4"/>
          <text>VEGF</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>In addition, VEGF receptor tyrosine kinase inhibitors, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sorafenib</infon>
          <location offset="1232" length="9"/>
          <text>sorafenib</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pazopanib</infon>
          <location offset="1246" length="9"/>
          <text>pazopanib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1306</offset>
        <text>In this review, we discuss potential molecular targets and novel therapeutic strategies that are being investigated for the treatment of cervical cancer.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18573490</id>
    <passage>
      <offset>0</offset>
      <text>Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.	Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne. However, molecular basis for these pharmacological properties is little known. We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (NF)-kappaB activation, which is closely linked to the inflammatory and immune disorders. In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM. LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB. Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity. Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.</text>
      <sentence>
        <offset>0</offset>
        <text>Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iminobenzoxathiolone</infon>
          <location offset="6" length="20"/>
          <text>iminobenzoxathiolone</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nuclear factor-kappab</infon>
          <location offset="45" length="21"/>
          <text>nuclear factor-kappaB</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inhibitory kappab</infon>
          <location offset="88" length="17"/>
          <text>inhibitory kappaB</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-1beta</infon>
          <location offset="138" length="17"/>
          <text>interleukin-1beta</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>212</offset>
        <text>Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzoxathiolone derivatives</infon>
          <location offset="212" length="27"/>
          <text>Benzoxathiolone derivatives</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>321</offset>
        <text>However, molecular basis for these pharmacological properties is little known.</text>
      </sentence>
      <sentence>
        <offset>400</offset>
        <text>We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (NF)-kappaB activation, which is closely linked to the inflammatory and immune disorders.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf)-kappab</infon>
          <location offset="517" length="10"/>
          <text>NF)-kappaB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>606</offset>
        <text>In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iminobenzoxathiolone</infon>
          <location offset="629" length="20"/>
          <text>iminobenzoxathiolone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappab) kinase beta</infon>
          <location offset="806" length="20"/>
          <text>IkappaB) kinase beta</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikkbeta</infon>
          <location offset="828" length="7"/>
          <text>IKKbeta</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="864" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>920</offset>
        <text>LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lyr-71</infon>
          <location offset="920" length="6"/>
          <text>LYR-71</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikkbeta</infon>
          <location offset="937" length="7"/>
          <text>IKKbeta</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappabalpha</infon>
          <location offset="985" length="12"/>
          <text>IkappaBalpha</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappabalpha</infon>
          <location offset="1077" length="12"/>
          <text>IkappaBalpha</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1143" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T19" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1154</offset>
        <text>Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lyr-71</infon>
          <location offset="1167" length="6"/>
          <text>LYR-71</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il)-1beta</infon>
          <location offset="1231" length="9"/>
          <text>IL)-1beta</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikkbeta</infon>
          <location offset="1306" length="7"/>
          <text>IKKbeta</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-1beta</infon>
          <location offset="1323" length="8"/>
          <text>IL-1beta</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1351</offset>
        <text>Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lyr-71</infon>
          <location offset="1367" length="6"/>
          <text>LYR-71</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikkbeta</infon>
          <location offset="1404" length="7"/>
          <text>IKKbeta</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1424" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1576" length="9"/>
          <text>cytokines</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18591256</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.	Constitutively active tyrosine kinases promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis. However, mechanisms underlying apoptotic inhibition have not been fully elucidated. In many settings, apoptosis occurs by mitochondrial cytochrome c release, which nucleates the Apaf-1/caspase-9 apoptosome. Here we report that the leukemogenic kinases, Bcr-Abl, FLT3/D835Y, and Tel-PDGFRbeta, all can inhibit apoptosome function. In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to Apaf-1, preventing cytochrome c-induced Apaf-1 oligomerization and caspase-9 recruitment. Hsp90beta interacted weakly with the apoptosome in untransformed cells. While Hsp90beta was phosphorylated at Ser 226/Ser 255 in untransformed cells, phosphorylation was absent in leukemic cells. Expression of mutant Hsp90beta (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1. In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance. These data provide an explanation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alterations in Hsp90beta-apoptosome interactions may contribute to chemoresistance in leukemias.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="53" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>117</offset>
        <text>Constitutively active tyrosine kinases promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis.</text>
      </sentence>
      <sentence>
        <offset>238</offset>
        <text>However, mechanisms underlying apoptotic inhibition have not been fully elucidated.</text>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>In many settings, apoptosis occurs by mitochondrial cytochrome c release, which nucleates the Apaf-1/caspase-9 apoptosome.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apaf-1/caspase-9</infon>
          <location offset="416" length="16"/>
          <text>Apaf-1/caspase-9</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>445</offset>
        <text>Here we report that the leukemogenic kinases, Bcr-Abl, FLT3/D835Y, and Tel-PDGFRbeta, all can inhibit apoptosome function.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="491" length="7"/>
          <text>Bcr-Abl</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3/d835y</infon>
          <location offset="500" length="10"/>
          <text>FLT3/D835Y</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tel-pdgfrbeta</infon>
          <location offset="516" length="13"/>
          <text>Tel-PDGFRbeta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to Apaf-1, preventing cytochrome c-induced Apaf-1 oligomerization and caspase-9 recruitment.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="649" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apaf-1</infon>
          <location offset="678" length="6"/>
          <text>Apaf-1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apaf-1</infon>
          <location offset="718" length="6"/>
          <text>Apaf-1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-9</infon>
          <location offset="745" length="9"/>
          <text>caspase-9</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>768</offset>
        <text>Hsp90beta interacted weakly with the apoptosome in untransformed cells.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="768" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>840</offset>
        <text>While Hsp90beta was phosphorylated at Ser 226/Ser 255 in untransformed cells, phosphorylation was absent in leukemic cells.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="846" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>964</offset>
        <text>Expression of mutant Hsp90beta (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="1205" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apaf-1</infon>
          <location offset="1218" length="6"/>
          <text>Apaf-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1226</offset>
        <text>In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="1229" length="7"/>
          <text>Bcr-Abl</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="1291" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1322" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gleevec</infon>
          <location offset="1332" length="7"/>
          <text>Gleevec</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1353</offset>
        <text>These data provide an explanation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alterations in Hsp90beta-apoptosome interactions may contribute to chemoresistance in leukemias.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsp90beta</infon>
          <location offset="1488" length="9"/>
          <text>Hsp90beta</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18602931</id>
    <passage>
      <offset>0</offset>
      <text>[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.	ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS. Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes. Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and pain. While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors. A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors. A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells. [3H]A-804598 labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg). No specific binding was observed in untransfected 1321N1 cells. The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P&lt;0.05). These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.</text>
      <sentence>
        <offset>0</offset>
        <text>[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="136" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>152</offset>
        <text>ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="166" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>289</offset>
        <text>Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="303" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-1beta</infon>
          <location offset="423" length="8"/>
          <text>IL-1beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>529</offset>
        <text>Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and pain.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptor</infon>
          <location offset="626" length="13"/>
          <text>P2X7 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>677</offset>
        <text>While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7</infon>
          <location offset="709" length="4"/>
          <text>P2X7</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-804598</infon>
          <location offset="733" length="8"/>
          <text>A-804598</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="915" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>931</offset>
        <text>A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-804598</infon>
          <location offset="931" length="8"/>
          <text>A-804598</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-1beta</infon>
          <location offset="992" length="8"/>
          <text>IL-1beta</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="1079" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T13" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1095</offset>
        <text>A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-804598</infon>
          <location offset="1095" length="8"/>
          <text>A-804598</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="1183" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1225</offset>
        <text>[3H]A-804598 labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg).</text>
      </sentence>
      <sentence>
        <offset>1336</offset>
        <text>No specific binding was observed in untransfected 1321N1 cells.</text>
      </sentence>
      <sentence>
        <offset>1400</offset>
        <text>The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P&lt;0.05).</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x</infon>
          <location offset="1432" length="3"/>
          <text>P2X</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="1544" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1577</offset>
        <text>These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-804598</infon>
          <location offset="1605" length="8"/>
          <text>A-804598</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="1680" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p2x7 receptors</infon>
          <location offset="1801" length="14"/>
          <text>P2X7 receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T26" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18610736</id>
    <passage>
      <offset>0</offset>
      <text>Role of transporter genes in cisplatin resistance.	The 50% inhibitory concentration (IC50) values for cisplatin from 60 cell lines of the National Cancer Institute (NCI), USA, were correlated with the microarray-based mRNA expression levels of 55 transporter genes. The transporters are known to be involved in multiple drug resistance and belong to different classes, e.g. lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes. The expression levels of 17 genes represented by 21 clones correlated significantly with the IC50 values for cisplatin. Hierarchical cluster analysis further enabled the prediction of the sensitivity or resistance of these cell lines to cisplatin with respect to the mRNA expression of these set of transporter genes under study. One among the 17 genes studied is ATP7B which is involved in the transport of copper ions across the cell membrane into the cell. We conclude that our microarray-based approach is a feasible and effective tool in identifying prognostic markers for drug resistance in antitumor therapy.</text>
      <sentence>
        <offset>0</offset>
        <text>Role of transporter genes in cisplatin resistance.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="29" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>51</offset>
        <text>The 50% inhibitory concentration (IC50) values for cisplatin from 60 cell lines of the National Cancer Institute (NCI), USA, were correlated with the microarray-based mRNA expression levels of 55 transporter genes.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="102" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>The transporters are known to be involved in multiple drug resistance and belong to different classes, e.g. lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutamate transporters of the solute carrier family 31</infon>
          <location offset="436" length="54"/>
          <text>glutamate transporters of the solute carrier family 31</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">copper transporters of the solute carrier family 31</infon>
          <location offset="492" length="51"/>
          <text>copper transporters of the solute carrier family 31</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atp-binding cassette</infon>
          <location offset="549" length="20"/>
          <text>ATP-binding cassette</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>595</offset>
        <text>The expression levels of 17 genes represented by 21 clones correlated significantly with the IC50 values for cisplatin.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="704" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>715</offset>
        <text>Hierarchical cluster analysis further enabled the prediction of the sensitivity or resistance of these cell lines to cisplatin with respect to the mRNA expression of these set of transporter genes under study.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="832" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>925</offset>
        <text>One among the 17 genes studied is ATP7B which is involved in the transport of copper ions across the cell membrane into the cell.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atp7b</infon>
          <location offset="959" length="5"/>
          <text>ATP7B</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper ions</infon>
          <location offset="1003" length="11"/>
          <text>copper ions</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1055</offset>
        <text>We conclude that our microarray-based approach is a feasible and effective tool in identifying prognostic markers for drug resistance in antitumor therapy.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18676772</id>
    <passage>
      <offset>0</offset>
      <text>Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.	PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo. EXPERIMENTAL DESIGN: Epithelial cells were purified from surgically resected esophagi. Telomerase activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay. To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (GRN163L) and live cell number was determined weekly. Apoptosis was evaluated by Annexin labeling and senescence by beta-galactosidase staining. For in vivo studies, severe combined immunodeficient mice were s.c. inoculated with adenocarcinoma cells and following appearance of palpable tumors, injected i.p. with saline or GRN163L. RESULTS: Telomerase activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells. The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis. GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir. Finally, the treatment with GRN163L led to a significant reduction in tumor volume in a subcutaneous tumor model. CONCLUSIONS: We show that telomerase activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of telomerase inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.</text>
      <sentence>
        <offset>0</offset>
        <text>Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="108" length="10"/>
          <text>telomerase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>139</offset>
        <text>PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="344" length="10"/>
          <text>telomerase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>EXPERIMENTAL DESIGN: Epithelial cells were purified from surgically resected esophagi.</text>
      </sentence>
      <sentence>
        <offset>491</offset>
        <text>Telomerase activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="491" length="10"/>
          <text>Telomerase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>635</offset>
        <text>To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (GRN163L) and live cell number was determined weekly.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="661" length="10"/>
          <text>telomerase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">grn163l</infon>
          <location offset="774" length="7"/>
          <text>GRN163L</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>827</offset>
        <text>Apoptosis was evaluated by Annexin labeling and senescence by beta-galactosidase staining.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-galactosidase</infon>
          <location offset="889" length="18"/>
          <text>beta-galactosidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>918</offset>
        <text>For in vivo studies, severe combined immunodeficient mice were s.c. inoculated with adenocarcinoma cells and following appearance of palpable tumors, injected i.p. with saline or GRN163L.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">grn163l</infon>
          <location offset="1097" length="7"/>
          <text>GRN163L</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1106</offset>
        <text>RESULTS: Telomerase activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="1115" length="10"/>
          <text>Telomerase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1255</offset>
        <text>The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">grn163l</infon>
          <location offset="1320" length="7"/>
          <text>GRN163L</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="1344" length="10"/>
          <text>telomerase</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1469</offset>
        <text>GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">grn163l</infon>
          <location offset="1469" length="7"/>
          <text>GRN163L</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1563" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ritonavir</infon>
          <location offset="1579" length="9"/>
          <text>ritonavir</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1590</offset>
        <text>Finally, the treatment with GRN163L led to a significant reduction in tumor volume in a subcutaneous tumor model.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">grn163l</infon>
          <location offset="1618" length="7"/>
          <text>GRN163L</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1704</offset>
        <text>CONCLUSIONS: We show that telomerase activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of telomerase inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="1730" length="10"/>
          <text>telomerase</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">telomerase</infon>
          <location offset="1833" length="10"/>
          <text>telomerase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18927209</id>
    <passage>
      <offset>0</offset>
      <text>A novel mTOR inhibitor is efficacious in a murine model of colitis.	Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium. Several compounds that possess antiproliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of colitis. Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis. In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis. In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells. In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function. In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR. Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis. Given that compounds with anticancer activity show promising anti-inflammatory efficacy, our findings reinforce the cross-therapeutic functionality of potential drugs.</text>
      <sentence>
        <offset>0</offset>
        <text>A novel mTOR inhibitor is efficacious in a murine model of colitis.</text>
      </sentence>
      <sentence>
        <offset>68</offset>
        <text>Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.</text>
      </sentence>
      <sentence>
        <offset>392</offset>
        <text>Several compounds that possess antiproliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of colitis.</text>
      </sentence>
      <sentence>
        <offset>545</offset>
        <text>Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mammalian target of rapamycin</infon>
          <location offset="545" length="29"/>
          <text>Mammalian target of rapamycin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="576" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>670</offset>
        <text>In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="747" length="5"/>
          <text>P2281</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>829</offset>
        <text>In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="914" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="929" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T17" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>966</offset>
        <text>In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1047" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-gamma</infon>
          <location offset="1072" length="9"/>
          <text>IFN-gamma</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="1101" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1169" length="5"/>
          <text>P2281</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1195</offset>
        <text>In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dextran sulfate sodium</infon>
          <location offset="1202" length="22"/>
          <text>dextran sulfate sodium</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1226" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1301" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1331" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1435" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1530" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1558" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1685" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1752" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1765" length="3"/>
          <text>DSS</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1791" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T40" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1797</offset>
        <text>Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.</text>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p2281</infon>
          <location offset="1854" length="5"/>
          <text>P2281</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dss</infon>
          <location offset="1896" length="3"/>
          <text>DSS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1990</offset>
        <text>Given that compounds with anticancer activity show promising anti-inflammatory efficacy, our findings reinforce the cross-therapeutic functionality of potential drugs.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19024103</id>
    <passage>
      <offset>0</offset>
      <text>Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.	BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers. Forty percent to fifty percent of glioblastoma multiforme (GBM) possess deregulated EGFR, which may contribute to the aggressive and refractory course of GBM. Therefore, blockade of EGFR signal transduction may be a promising treatment strategy for GBM. METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of F90 against SHG-44 in vitro and in vivo. Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, p-JNK, p-P38, Bcl2 and P53 proteins. RESULTS: F90 inhibited the cell proliferation in a dose-dependent manner in vitro. The growth of SHG-44 tumor xenografts was suppressed by F90 at a high dose level (100 mg x kg(-1) x d(-1)). Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro. Down-regulated Bcl2 protein and up-regulated P53 protein were also observed. CONCLUSIONS: The results demonstrate that F90 is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that F90 may be a new therapeutic option for treatment of GBM.</text>
      <sentence>
        <offset>0</offset>
        <text>Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="22" length="3"/>
          <text>F90</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="155" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="189" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>342</offset>
        <text>Forty percent to fifty percent of glioblastoma multiforme (GBM) possess deregulated EGFR, which may contribute to the aggressive and refractory course of GBM.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="426" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>501</offset>
        <text>Therefore, blockade of EGFR signal transduction may be a promising treatment strategy for GBM.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="524" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>596</offset>
        <text>METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of F90 against SHG-44 in vitro and in vivo.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="714" length="3"/>
          <text>F90</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>755</offset>
        <text>Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, p-JNK, p-P38, Bcl2 and P53 proteins.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="846" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="855" length="3"/>
          <text>P53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>869</offset>
        <text>RESULTS: F90 inhibited the cell proliferation in a dose-dependent manner in vitro.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="878" length="3"/>
          <text>F90</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>952</offset>
        <text>The growth of SHG-44 tumor xenografts was suppressed by F90 at a high dose level (100 mg x kg(-1) x d(-1)).</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="1008" length="3"/>
          <text>F90</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1060</offset>
        <text>Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1079" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk1</infon>
          <location offset="1137" length="4"/>
          <text>ERK1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1143" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p38</infon>
          <location offset="1151" length="3"/>
          <text>P38</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="1205" length="3"/>
          <text>F90</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1232</offset>
        <text>Down-regulated Bcl2 protein and up-regulated P53 protein were also observed.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="1247" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1277" length="3"/>
          <text>P53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1309</offset>
        <text>CONCLUSIONS: The results demonstrate that F90 is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that F90 may be a new therapeutic option for treatment of GBM.</text>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="1351" length="3"/>
          <text>F90</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">f90</infon>
          <location offset="1467" length="3"/>
          <text>F90</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19047160</id>
    <passage>
      <offset>0</offset>
      <text>Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.	Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia. Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease. In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance. Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms. We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding. Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib. Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML. Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity. In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn. Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance.</text>
      <sentence>
        <offset>0</offset>
        <text>Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.</text>
        <annotation id="T0">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="28" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="52" length="7"/>
          <text>BCR-ABL</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgp</infon>
          <location offset="61" length="3"/>
          <text>Pgp</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src kinase</infon>
          <location offset="69" length="10"/>
          <text>Src kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T3" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T1" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T0" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="138" length="7"/>
          <text>Bcr-Abl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="280" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="446" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dasatinib</infon>
          <location offset="459" length="9"/>
          <text>dasatinib</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="510" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="532" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>561</offset>
        <text>In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="596" length="9"/>
          <text>nilotinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>675</offset>
        <text>Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="693" length="7"/>
          <text>BCR-ABL</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">multidrug resistance gene</infon>
          <location offset="705" length="25"/>
          <text>multidrug resistance gene</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="732" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>785</offset>
        <text>We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="800" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="867" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">verapamil</infon>
          <location offset="889" length="9"/>
          <text>verapamil</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">psc833</infon>
          <location offset="902" length="6"/>
          <text>PSC833</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T22" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T25" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T24" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>927</offset>
        <text>Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53/56 lyn</infon>
          <location offset="954" length="10"/>
          <text>p53/56 Lyn</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1058" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="1121" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1132</offset>
        <text>Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="1153" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn mrna</infon>
          <location offset="1207" length="8"/>
          <text>Lyn mRNA</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T31" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.</text>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">src kinase inhibitors</infon>
          <location offset="1263" length="21"/>
          <text>Src kinase inhibitors</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pp1</infon>
          <location offset="1286" length="3"/>
          <text>PP1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pp2</infon>
          <location offset="1294" length="3"/>
          <text>PP2</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="1362" length="7"/>
          <text>Bcr-Abl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1396</offset>
        <text>In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dasatinib</infon>
          <location offset="1409" length="9"/>
          <text>dasatinib</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="1499" length="7"/>
          <text>BCR-ABL</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1511" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr-abl</infon>
          <location offset="1545" length="7"/>
          <text>Bcr-Abl</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53/56 lyn</infon>
          <location offset="1578" length="10"/>
          <text>p53/56 Lyn</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T38" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1590</offset>
        <text>Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance.</text>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1651" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1716" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nilotinib</infon>
          <location offset="1723" length="9"/>
          <text>nilotinib</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T44" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T46" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19056662</id>
    <passage>
      <offset>0</offset>
      <text>Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.	Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear. We therefore investigated the effects of FOS on expressions of genes involved with calcium absorption in rat colorectal mucosa cells. After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b). The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression. Because FOS could not directly affect gene expression, SCFA formed as fermentation products of FOS were considered as likely intermediates. SCFA (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of TRPV6. To ascertain the effects of SCFA on mRNA expression, a genomic clone of TRPV6 was isolated. Using luciferase reporter assay, a segment between -71 nucleotides and the translation start site was found to contain a positive responsive element to SCFA. These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6. We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.</text>
      <sentence>
        <offset>0</offset>
        <text>Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transient receptor potential vanilloid type 6</infon>
          <location offset="42" length="45"/>
          <text>transient receptor potential vanilloid type 6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>125</offset>
        <text>Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="149" length="3"/>
          <text>FOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>294</offset>
        <text>We therefore investigated the effects of FOS on expressions of genes involved with calcium absorption in rat colorectal mucosa cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="335" length="3"/>
          <text>FOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>428</offset>
        <text>After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="460" length="3"/>
          <text>FOS</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transient receptor potential vanilloid type 6</infon>
          <location offset="533" length="45"/>
          <text>transient receptor potential vanilloid type 6</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="580" length="5"/>
          <text>TRPV6</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">calbindin-d9k</infon>
          <location offset="588" length="13"/>
          <text>calbindin-D9k</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">calcium-atpase 1b</infon>
          <location offset="623" length="17"/>
          <text>calcium-ATPase 1b</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pmca1b</infon>
          <location offset="642" length="6"/>
          <text>PMCA1b</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T5" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T5" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>651</offset>
        <text>The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="655" length="3"/>
          <text>FOS</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="688" length="5"/>
          <text>TRPV6</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">calbindin-d9k</infon>
          <location offset="698" length="13"/>
          <text>calbindin-D9k</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pmca1b</infon>
          <location offset="731" length="6"/>
          <text>PMCA1b</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T11" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>750</offset>
        <text>Because FOS could not directly affect gene expression, SCFA formed as fermentation products of FOS were considered as likely intermediates.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="758" length="3"/>
          <text>FOS</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="845" length="3"/>
          <text>FOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>SCFA (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of TRPV6.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="1022" length="5"/>
          <text>TRPV6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1029</offset>
        <text>To ascertain the effects of SCFA on mRNA expression, a genomic clone of TRPV6 was isolated.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="1101" length="5"/>
          <text>TRPV6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1121</offset>
        <text>Using luciferase reporter assay, a segment between -71 nucleotides and the translation start site was found to contain a positive responsive element to SCFA.</text>
      </sentence>
      <sentence>
        <offset>1279</offset>
        <text>These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="1306" length="3"/>
          <text>FOS</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="1371" length="5"/>
          <text>TRPV6</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="1471" length="3"/>
          <text>FOS</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="1525" length="5"/>
          <text>TRPV6</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T26" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1532</offset>
        <text>We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trpv6</infon>
          <location offset="1598" length="5"/>
          <text>TRPV6</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fos</infon>
          <location offset="1708" length="3"/>
          <text>FOS</text>
        </annotation>
        <relation id="">
          <infon key="type">DRUG-TARGET</infon>
          <node refid="T30" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
</collection>
